Document is current
Any future updates will be listed below
-
Authors
Chiaretti, Sabina
Blum, Sabine https://orcid.org/0000-0003-2275-3081
Leguay, Thibaut https://orcid.org/0000-0002-3123-4948
Balsat, Marie
Salek, Cyril https://orcid.org/0000-0002-0021-3247
Fracchiolla, Nicola
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Rijneveld, Anita
Papayannidis, Cristina
Nunes, Albertina
Wilke, Anne Christine
Machherndl-Spandl, Sigrid
Wartiovaara-Kautto, Ulla
Choudhry, Jessica
Maraboina, Ravikanth
Zugmaier, Gerhard https://orcid.org/0000-0001-6879-2671
Mergen, Noemi
Ochs, Andreas
Rambaldi, Alessandro https://orcid.org/0000-0002-3739-7502
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 19 December 2025
Revised: 19 March 2026
Accepted: 14 April 2026
First Online: 2 May 2026
Competing interests
: Sabina Chiaretti received honoraria for advisory boards from Amgen, Gilead, Incyte, Pfizer, and Shire. Sabine Blum received travel support from AbbVie. Thibaut Leguay and Anita Rijneveld have no competing interests to disclose. Marie Balsat received honoraria from Amgen, Incyte, Jazz Pharmaceutical, Novartis, and Servier. Cyril Salek received honoraria from Amgen, Angelini, Bristol-Myers Squibb, and Pfizer. Nicola Fracchiolla received honoraria from Amgen, AbbVie, Gilead, and Pfizer for travel, speakers’ bureau, accommodation, and advisory board meetings. Alexandros Spyridonidis received honoraria for scientific advisory board from Amgen, Gilead, MSD, and Novartis. Cristina Papayannidis received honoraria from Amgen, Novartis, Pfizer, Shire, and Teva Pharmaceutical for travel, sponsored lectures, and advisory board meetings. Albertina Nunes received honoraria from Amgen, AbbVie, Novartis, Pfizer, Roche, and Sobi for sponsored lectures and meetings. Anne Christine Wilke received honoraria from AbbVie and Roche, and travel grants from AbbVie, Gilead/Kite, and Lilly. Sigrid Machherndl-Spandl received honoraria from AbbVie, Alexion, Amgen, BMS/Celgene, Daiichi-Sankyo, Jazz, Johnson & Johnson, Novartis, Pfizer, and Servier. Ulla Wartiovaara-Kautto received honoraria from Amgen, Incyte, and Pfizer. Ravikanth Maraboina is an employee at IQVIA which received funding from Amgen to perform this study. Gerhard Zugmaier is employed by Amgen, owns stock in Amgen, and holds patents relating to blinatumomab. Jessica Choudhry, Noemi Mergen, and Andreas Ochs are employees at Amgen and hold its stock. Alessandro Rambaldi received honoraria from Amgen, Gilead, Novartis, and Pfizer for scientific advisory board meetings.
